Article
Virology
Louis Nevejan, Sien Ombelet, Lies Laenen, Els Keyaerts, Thomas Demuyser, Lucie Seyler, Oriane Soetens, Els Van Nedervelde, Reinout Naesens, Dieter Geysels, Walter Verstrepen, Lien Cattoir, Steven Martens, Charlotte Michel, Elise Mathieu, Marijke Reynders, Anton Evenepoel, Jorn Hellemans, Merijn Vanhee, Koen Magerman, Justine Maes, Veerle Matheeussen, Helene Boogaerts, Katrien Lagrou, Lize Cuypers, Emmanuel Andre
Summary: Through retrospective analysis of hospitalized patients, it was found that unvaccinated individuals have a higher risk of moderate/severe/critical/fatal COVID-19, regardless of whether they are infected with the Omicron or Delta variant. Among adults infected with the Omicron variant and have moderate/severe/critical/fatal COVID-19, immunocompromised patients are at increased risk of in-hospital mortality.
Review
Environmental Sciences
Neelam Sharma, Shahid Nazir Wani, Tapan Behl, Sukhbir Singh, Ishrat Zahoor, Aayush Sehgal, Saurabh Bhatia, Ahmed Al-Harrasi, Lotfi Aleya, Simona Bungau
Summary: COVID-19 disease has led to a significant increase in cases of mucormycosis infection in India, primarily among individuals recovering from COVID-19. This poses a serious threat to immunocompromised COVID-19 patients and is associated with severe clinical complications and elevated death rate.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2023)
Article
Immunology
Manica Negahdaripour, Mojtaba Shafiekhani, Seyed Mohammad Iman Moezzi, Sogand Amiri, Shiva Rasekh, Ashkan Bagheri, Pouria Mosaddeghi, Afsaneh Vazin
Summary: This review focuses on the challenges and considerations of COVID-19 vaccination in specific populations, such as patients with autoimmune diseases and those receiving immunosuppressive treatments. While confirmed data is lacking, reaching a consensus on vaccination for these populations is crucial, along with the need for further research and clinical trials to address these issues.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Letter
Infectious Diseases
D'Abramo Alessandra, Vita Serena, Nicastri Emanuele
Summary: This study examines the use of SARS-CoV-2 antivirals and/or monoclonal antibodies in immunocompromised patients, supporting the use of early combination therapy and advocating for a tailored and standardized therapeutic approach in this population.
BMC INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, Mario Cruciani, Matteo Zani, Ellen K. Gorman, Daniele Focosi, Arturo Casadevall, Michael J. Joyner
Summary: Patients who are immunocompromised have increased risk for morbidity and mortality associated with COVID-19. Transfusion of COVID-19 convalescent plasma is associated with a mortality benefit for these patients.
Editorial Material
Medicine, General & Internal
Eric J. Rubin, Lindsey R. Baden, Stephen Morrissey
Summary: This interview discusses the prevention and treatment of Covid-19 in immunocompromised patients, as well as the impact on viral evolution.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Infectious Diseases
Daniele Focosi, Fabrizio Maggi, Alessandra D'Abramo, Emanuele Nicastri, David J. Sullivan
Summary: After the third year of the COVID-19 pandemic, immunocompromised patients face persistent infection and ineffective treatment with standard antiviral monotherapy. Combined antiviral therapies can mitigate these consequences.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Jin-Wen Song, Wei Hu, Lili Shen, Fu-Sheng Wang
Summary: People with compromised immune systems are at a higher risk of severe COVID-19 complications. Current clinical trials for COVID-19 vaccines have not included this population, prompting the need for studies on vaccine efficacy and optimal vaccination strategies.
CHINESE MEDICAL JOURNAL
(2022)
Editorial Material
Oncology
Xiangdong Wang, Charles A. Powell
Summary: The Omicron variant has the potential to rapidly spread worldwide, with infections likely to predominate in unvaccinated and immunodeficient populations. Therefore, promoting vaccinations, boosters, and accessible testing is crucial for preventing disease transmission.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Virology
Eloy E. Ordaya, Paschalis Vergidis, Raymund R. Razonable, Joseph D. Yao, Elena Beam
Summary: This study found that most SARS-CoV-2 Omicron subvariants in COVID-19 patients who received Tixagevimab-cilgavimab showed reduced susceptibility to the antibody. Some patients also showed high resistance to Bebtelovimab. The results highlight the importance of genomic surveillance and identification of new resistant variants.
JOURNAL OF CLINICAL VIROLOGY
(2023)
Review
Medicine, General & Internal
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, Onder Ergonul, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Jerome H. Kim, Bhavna Lall, Heidi J. Larson, Denise Naniche, Timothy Sheahan, Nathalie Strub-Wourgaft, Samba O. Sow, Annelies Wilder-Smith, Prashant Yadav, Maria Elena Bottazzi
Summary: The COVID-19 pandemic has had a disproportionate impact on immunocompromised patients, who are at increased risk for impaired vaccine responses, severe disease, prolonged hospitalizations, and deaths. People with deficiencies in lymphocyte number or function, such as transplant recipients and those with hematologic malignancies, are particularly at risk. Their impaired immune responses to vaccination and infection leave them more vulnerable to high viral loads and severe complications of COVID-19, which can in turn lead to disease progression, development of immune escape variants, and transmission of infection.
Article
Medicine, General & Internal
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das
Summary: This study compared the safety, reactogenicity, and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine with the previously authorized mRNA-1273 booster. The mRNA-1273.214 elicited superior neutralizing antibody responses against the omicron variant compared to mRNA-1273, without evident safety concerns.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Patricia O. Guimaraes, Daniel Quirk, Remo H. Furtado, Lilia N. Maia, Jose F. Saraiva, Murillo O. Antunes, Roberto Kalil Filho, Vagner M. Junior, Alexandre M. Soeiro, Alexandre P. Tognon, Viviane C. Veiga, Priscilla A. Martins, Diogo D. F. Moia, Bruna S. Sampaio, Silvia R. L. Assis, Ronaldo V. P. Soares, Luciana P. A. Piano, Kleber Castilho, Roberta G. R. A. P. Momesso, Frederico Monfardini, Helio P. Guimaraes, Dario Ponce de Leon, Majori Dulcine, Marcia R. T. Pinheiro, Levent M. Gunay, J. Jasper Deuring, Luiz V. Rizzo, Tamas Koncz, Otavio Berwanger
Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Clinical Neurology
Simone Beretta, Viviana Cristillo, Giorgia Camera, Carlo Morotti Colleoni, Gaia Pellitteri, Beatrice Viti, Elisa Bianchi, Stefano Gipponi, Maria Grimoldi, Mariarosaria Valente, Susanna Guttmann, Maria Sofia Cotelli, Pasquale Palumbo, Giorgio Gelosa, Stefano Meletti, Cristina Schenone, Donatella Ottaviani, Massimo Filippi, Andrea Zini, Paola Basilico, Lucia Tancredi, Pietro Cortelli, Massimiliano Braga, Valeria De Giuli, Serenella Servidei, Damiano Paolicelli, Federico Verde, Stefano Caproni, Antonio Pisani, Vincenzina Lo Re, Luca Massacesi, Daria Valeria Roccatagliata, Paolo Manganotti, Daniele Spitaleri, Anna Formenti, Marta Piccoli, Silvia Marino, Paola Polverino, Umberto Aguglia, Raffaele Ornello, Elisabetta Perego, Gabriele Siciliano, Paola Merlo, Marco Capobianco, Leonardo Pantoni, Alessandra Lugaresi, Stefania Angelocola, Anna De Rosa, Maria Sessa, Ettore Beghi, Elio Clemente Agostoni, Salvatore Monaco, Alessandro Padovani, Alberto Priori, Vincenzo Silani, Gioacchino Tedeschi, Carlo Ferrarese
Summary: This study aimed to analyze the incidence dynamics and long-term functional outcome of neurological disorders associated with COVID-19 infection. Through a survey and follow-up of hospitalized patients in 38 centers in Italy and the Republic of San Marino, it was found that the incidence of neurological disorders decreased over different stages of the pandemic. Most patients achieved a favorable functional outcome, but mild symptoms commonly persisted for more than 6 months.
Article
Microbiology
David Klank, Bernd Claus, Raoul Bergner, Peter Paschka
Summary: Medical care for immunocompromised patients with COVID-19 infection is challenging. Vaccination responses are poor in patients with oncological or autoimmune diseases, requiring rapid and effective care. Monoclonal antibodies (mAb) provide an effective therapeutic option with favorable toxicity.
Article
Cell Biology
Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, Naomi Smorenburg, Dennis Schmitz, Florian Zwagemaker, Arianne B. van Gageldonk-Lafeber, Susan J. M. Hahne, Chantal Reusken, Mirjam J. Knol, Dirk Eggink
Summary: A study in the Netherlands found an increased risk of infection by the Beta, Gamma, or Delta variants compared with the Alpha variant after vaccination. However, this effect was more pronounced in the first 14 to 59 days after complete vaccination. In contrast, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Luca M. Zaeck, Mart M. Lamers, Babs E. Verstrepen, Theo M. Bestebroer, Martin E. van Royen, Hannelore Gotz, Marc C. Shamier, Leanne P. M. van Leeuwen, Katharina S. Schmitz, Kimberley Alblas, Suzanne van Efferen, Susanne Bogers, Sandra Scherbeijn, Guus F. Rimmelzwaan, Eric C. M. van Gorp, Marion P. G. Koopmans, Bart L. Haagmans, Corine H. GeurtsvanKessel, Rory D. de Vries
Summary: In July 2022, the monkeypox outbreak was declared an international public health emergency. Historic smallpox vaccination and monkeypox virus infection can generate MPXV-neutralizing antibodies, but vaccination with MVA-BN results in lower levels of these antibodies. Further studies are needed to assess the efficacy of the MVA-BN vaccine in at-risk populations.
Article
Immunology
T. Tramper, D. L. Roelen, S. H. Brand-Schaaf, J. A. Kal-van Gestel, M. M. L. Kho, M. E. J. Reinders, J. I. Roodnat, J. van de Wetering, M. G. H. Betjes, A. E. de Weerd
Summary: In this retrospective analysis, the impact of donor-specific antibodies (DSA) in HLA-incompatible living donor kidney transplant recipients was studied. The results showed that recipients with DSA had inferior graft survival compared to those without DSA, and this effect was independent of the flowcytometric crossmatch, MFI value, HLA class, and origin of DSA.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Leanne P. M. H. van Leeuwen, Marloes Grobben, Corine GeurtsvanKessel, Pauline Ellerbroek, Godelieve de Bree, Judith Potjewijd, Abraham H. Rutgers, Hetty Jolink, Frank van de Veerdonk, Marit L. van Gils, Rory de Vries, Virgil A. S. H. Dalm, VACOPID Res Grp
Summary: This study investigated the immune responses of 473 patients with inborn errors of immunity (IEI) 6 months after receiving mRNA-1273 COVID-19 vaccines. The results showed that antibody titers and T cell responses in IEI patients also declined after 6 months of vaccination, and were more likely to drop below normal levels compared to healthy individuals. Additionally, the effectiveness of a third mRNA COVID-19 vaccine was limited in patients with common variable immunodeficiency (CVID) who did not seroconvert after previous vaccinations.
JOURNAL OF CLINICAL IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Mirjam Simoons, Kishan A. T. Naipal, Huib de Jong, Caroline M. den Hoed, Brenda C. M. de Winter, Midas B. Mulder
Summary: Oral antibiotics coadministration can decrease the exposure to mycophenolic acid (MPA) by reducing enzyme activity, which could result in rejection in solid organ transplant recipients. This interaction is clinically significant, especially when therapeutic drug monitoring frequency is low.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2023)
Article
Gastroenterology & Hepatology
Anne J. Klompenhouwer, Adriaan Moelker, Sarwa D. Murad, Caroline M. den Hoed, Raoel Maan
Summary: Intrahepatic arterioportal fistula (IAPF) is a rare cause of portal hypertension. The aim of treatment is to restore normal portal hemodynamics by closing the shunt. This report describes a case of idiopathic IAPF with severe portal hypertension complicated by portal enteropathy, vomiting, gastrointestinal hemorrhage, and sepsis. The patient was successfully treated with portal embolization.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY
(2024)
Article
Medicine, General & Internal
Sophie C. Froelke, Pim Bouwmans, A. Lianne Messchendorp, Johanna P. M. Vervoort, Alferso C. Abrahams, Aiko P. J. de Vries, Pythia T. Nieuwkerk, Marc H. Hemmelder, Ron T. Gansevoort, Luuk B. Hilbrands, Marlies E. J. Reinders, Jan-Stephan F. Sanders, Frederike J. Bemelman, Suzanne E. Geerlings, RECOVAC Collaborators
Summary: This study aimed to analyze the change in adherence to preventive measures after vaccination and awareness of antibody response in kidney transplant recipients (KTRs). The findings showed that adherence decreased after SARS-CoV-2 vaccination and in KTRs who were aware of a subsequent antibody response. However, preventive measures were effective in this vulnerable group, regardless of vaccination status.
Article
Surgery
Marry de Klerk, Judith A. Kal-van Gestel, Dave Roelen, Michiel G. H. Betjes, Annelies E. de Weerd, Marlies E. J. Reinders, Jacqueline Van de Wetering, Marcia M. L. Kho, Kristiaan Glorie, Joke I. Roodnat
Summary: Computerized integration of alternative transplantation programs (CIAT) is a kidney-exchange program that increases the chances of difficult-to-match patients by allowing AB0- and/or HLA-incompatible allocation and prioritizing highly-immunized and long waiting candidates. In a pilot study, CIAT transplanted the highest number of incompatible couples (35%), as well as a significant number of sHI patients (18%) and LW patients (20%). CIAT is a powerful addition to the limited number of programs available for difficult-to-match patients.
TRANSPLANT INTERNATIONAL
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
N. Wijbenga, R. A. Hoek, B. J. Mathot, L. Seghers, D. Bos, O. C. Manintveld, M. E. Hellemons
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
N. Wijbenga, M. J. van Kekem, M. M. Goedendorp-Sluimer, S. Roest, J. J. Brugts, K. Caliskan, A. A. Constantinescu, D. Bos, M. E. Hellemons, O. C. Manintveld
JOURNAL OF HEART AND LUNG TRANSPLANTATION
(2023)
Article
Surgery
Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink
Summary: Alemtuzumab is an effective treatment for severe kidney transplant rejection, but it results in long-lasting lymphocyte depletion and is associated with frequent infections and worse patient survival outcomes.
TRANSPLANT INTERNATIONAL
(2023)